AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

We are getting questions from farmers and accountants wondering if Pandemic Assistance Revenue Program (PARP) payments are still going to be made in 2023. Many are tidying up taxes for 2023 ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

Figure 2: Classification of the poly-ADP-ribose-polymerase (PARP) family according to the structural model proposed by Kleine et al.7. To identify the PARP10 residues that are post-translationally ...

Idience’s focus on anticancer drugs that could transform patient quality of life is exemplified by its lead asset IDX-1197, a PARP inhibitor that is currently in a phase 1b/2a basket study with ...

If confirmed in further studies, the findings suggest that it may be time to reassess current treatment with PARP (poly(ADP-ribose) polymerase) inhibitor drugs, which block the ability of cells ...

PARP drugs work by interfering with cancer cells ... showing improved PFS and quality-of-life when used as maintenance therapy for patients whose disease had not progressed during first-line ...